CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, genitourinary, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing trials in breast, genitourinary, lung and select hematologic cancers, and refer appropriate patients for study participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in the individualization of care for patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms on the basis of new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Jonathan W Friedberg, MD, MMSc
  Samuel E Durand Professor of Medicine
  Director, James P Wilmot Cancer Institute
  University of Rochester
  Rochester, New York
  
  Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Novartis.
  
  Irene M Ghobrial, MD
  Professor of Medicine
  Lavine Family Chair of Preventative Cancer Therapies
  Director, Center for Prevention of Progression of Blood Cancers
  Director, Translational Research in Multiple Myeloma
  Director, Clinical Investigator Research Program
  Director, Michele and Steven Kirsch Laboratory
  Harvard Medical School
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Aptitude Health, GlaxoSmithKline, GNS Healthcare; Consulting Agreements and Speaker Bureau: AbbVie Inc, Adaptive Biotechnologies Corporation, Aptitude Health, Bristol-Myers Squibb Company, Cellectar Biosciences Inc, Curio Science, Genentech, a member of the Roche Group, GlaxoSmithKline, GNS Healthcare, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology.
  
  John V Heymach, MD, PhD
  Professor and Chair
  Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Spectrum Pharmaceuticals Inc; Licensing and Fees: Spectrum Pharmaceuticals Inc.
  
  Maha Hussain, MD, FACP, FASCO
  Genevieve Teuton Professor of Medicine
  Division of Hematology/Oncology
  Deputy Director
  Robert H Lurie Comprehensive Cancer Center
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pfizer Inc; Contracted Research (to Institution): Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Pfizer Inc, The Prostate Cancer Clinical Trials Consortium; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Phillips Gilmore Oncology Communications Inc, Precisca, Sanofi Genzyme.
  
  Virginia Kaklamani, MD, DSc
  Professor of Medicine
  Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
  AB Alexander Distinguished Chair in Oncology
  Associate Director for Clinical Research
  Leader of the Breast Cancer Program
  UT Health San Antonio
  The University of Texas MD Anderson Cancer Center
  San Antonio, Texas
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Sanofi Genzyme; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc.
  
  Nancy U Lin, MD
  Associate Professor of Medicine
  Harvard Medical School
  Associate Chief, Division of Breast Oncology
  Director, Metastatic Breast Cancer Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: Aleta Biotherapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Denali Therapeutics, Novartis, Nuvation Bio, Olema Oncology, Pfizer Inc, Prelude Therapeutics, Seagen Inc, Suzhou Zanrong Pharmaceutical Technology Co Ltd; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Seagen Inc, Suzhou Zanrong Pharmaceutical Technology Co Ltd.
  
  Stephen V Liu, MD
  Associate Professor of Medicine
  Georgetown University Hospital
  Washington, DC
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Inivata, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc; Contracted Research: Alkermes, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Debiopharm Group, Elevation Oncology, Genentech, a member of the Roche Group, Lilly, Merck, Merus BV, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Advantagene Inc, Candel Therapeutics.
  
  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Anne and Bernard Gray Family Chair in Cancer
  Chief Medical Officer
  Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.
  
  Elizabeth R Plimack, MD, MS
  Chief, Division of Genitourinary Medical Oncology
  Director, Genitourinary Clinical Research
  Professor, Department of Hematology/Oncology
  Fox Chase Cancer Center
  Temple Health
  Philadelphia, Pennsylvania
  
  Advisory Committee: Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Associate Editor, Blood
  Vancouver, British Columbia, Canada
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Oncology, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Sanofi Genzyme, and Seagen Inc.
  
  Release date: June 2021
  Expiration date: June 2022